vs
OptimizeRx Corp（OPRX）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是OptimizeRx Corp的1.1倍（$35.5M vs $32.2M），OptimizeRx Corp净利率更高（15.6% vs -304.2%，领先319.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -0.2%），OptimizeRx Corp自由现金流更多（$7.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 28.0%）
OptimizeRx Corp是一家总部位于美国的数字健康科技企业，为生命科学公司、医疗机构及药房合作伙伴提供患者参与、药物可负担性和临床沟通相关解决方案，核心产品包括数字购药优惠工具、患者支持项目等，助力提升药物可及性与用药依从性。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
OPRX vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.1倍
$32.2M
营收增速更快
RXRX
高出682.0%
-0.2%
净利率更高
OPRX
高出319.8%
-304.2%
自由现金流更多
OPRX
多$54.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
28.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.2M | $35.5M |
| 净利润 | $5.0M | $-108.1M |
| 毛利率 | 74.8% | 59.8% |
| 营业利润率 | 26.6% | -304.8% |
| 净利率 | 15.6% | -304.2% |
| 营收同比 | -0.2% | 681.7% |
| 净利润同比 | 6535.9% | 39.6% |
| 每股收益（稀释后） | $0.27 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPRXRXRX
| Q4 25 | $32.2M | $35.5M | ||
| Q3 25 | $26.1M | $5.2M | ||
| Q2 25 | $29.2M | $19.2M | ||
| Q1 25 | $21.9M | $14.7M | ||
| Q4 24 | $32.3M | $4.5M | ||
| Q3 24 | $21.3M | $26.1M | ||
| Q2 24 | $18.8M | $14.4M | ||
| Q1 24 | $19.7M | $13.8M |
净利润OPRXRXRX
| Q4 25 | $5.0M | $-108.1M | ||
| Q3 25 | $779.0K | $-162.3M | ||
| Q2 25 | $1.5M | $-171.9M | ||
| Q1 25 | $-2.2M | $-202.5M | ||
| Q4 24 | $-78.0K | $-178.9M | ||
| Q3 24 | $-9.1M | $-95.8M | ||
| Q2 24 | $-4.0M | $-97.5M | ||
| Q1 24 | $-6.9M | $-91.4M |
毛利率OPRXRXRX
| Q4 25 | 74.8% | 59.8% | ||
| Q3 25 | 67.2% | -183.8% | ||
| Q2 25 | 63.8% | -4.9% | ||
| Q1 25 | 60.9% | -48.0% | ||
| Q4 24 | 68.1% | -181.4% | ||
| Q3 24 | 63.1% | 53.7% | ||
| Q2 24 | 62.2% | 36.2% | ||
| Q1 24 | 62.0% | 19.1% |
营业利润率OPRXRXRX
| Q4 25 | 26.6% | -304.8% | ||
| Q3 25 | 7.9% | -3327.6% | ||
| Q2 25 | 10.9% | -916.8% | ||
| Q1 25 | -9.6% | -1297.9% | ||
| Q4 24 | 11.2% | -4042.4% | ||
| Q3 24 | -40.2% | -377.1% | ||
| Q2 24 | -19.9% | -697.4% | ||
| Q1 24 | -25.5% | -698.4% |
净利率OPRXRXRX
| Q4 25 | 15.6% | -304.2% | ||
| Q3 25 | 3.0% | -3135.3% | ||
| Q2 25 | 5.2% | -894.2% | ||
| Q1 25 | -10.0% | -1373.3% | ||
| Q4 24 | -0.2% | -3935.5% | ||
| Q3 24 | -42.8% | -367.5% | ||
| Q2 24 | -21.3% | -676.6% | ||
| Q1 24 | -35.0% | -662.4% |
每股收益（稀释后）OPRXRXRX
| Q4 25 | $0.27 | $-0.17 | ||
| Q3 25 | $0.04 | $-0.36 | ||
| Q2 25 | $0.08 | $-0.41 | ||
| Q1 25 | $-0.12 | $-0.50 | ||
| Q4 24 | $0.00 | $-0.56 | ||
| Q3 24 | $-0.50 | $-0.34 | ||
| Q2 24 | $-0.22 | $-0.40 | ||
| Q1 24 | $-0.38 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $743.3M |
| 总债务越低越好 | $26.3M | $9.6M |
| 股东权益账面价值 | $128.3M | $1.1B |
| 总资产 | $176.9M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.20× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资OPRXRXRX
| Q4 25 | $23.4M | $743.3M | ||
| Q3 25 | $19.5M | $659.8M | ||
| Q2 25 | $16.6M | $525.1M | ||
| Q1 25 | $16.6M | $500.5M | ||
| Q4 24 | $13.4M | $594.4M | ||
| Q3 24 | $16.1M | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务OPRXRXRX
| Q4 25 | $26.3M | $9.6M | ||
| Q3 25 | $28.8M | $11.9M | ||
| Q2 25 | $29.3M | $14.2M | ||
| Q1 25 | $33.8M | $16.4M | ||
| Q4 24 | $34.3M | $19.0M | ||
| Q3 24 | $36.8M | $20.5M | ||
| Q2 24 | $37.3M | $22.9M | ||
| Q1 24 | $37.8M | — |
股东权益OPRXRXRX
| Q4 25 | $128.3M | $1.1B | ||
| Q3 25 | $122.3M | $1.0B | ||
| Q2 25 | $119.3M | $919.1M | ||
| Q1 25 | $116.3M | $933.9M | ||
| Q4 24 | $117.0M | $1.0B | ||
| Q3 24 | $114.5M | $524.6M | ||
| Q2 24 | $121.0M | $584.4M | ||
| Q1 24 | $122.5M | $401.2M |
总资产OPRXRXRX
| Q4 25 | $176.9M | $1.5B | ||
| Q3 25 | $170.3M | $1.4B | ||
| Q2 25 | $169.3M | $1.3B | ||
| Q1 25 | $167.8M | $1.3B | ||
| Q4 24 | $171.2M | $1.4B | ||
| Q3 24 | $165.2M | $726.5M | ||
| Q2 24 | $172.9M | $775.9M | ||
| Q1 24 | $176.4M | $557.8M |
负债/权益比OPRXRXRX
| Q4 25 | 0.20× | 0.01× | ||
| Q3 25 | 0.24× | 0.01× | ||
| Q2 25 | 0.25× | 0.02× | ||
| Q1 25 | 0.29× | 0.02× | ||
| Q4 24 | 0.29× | 0.02× | ||
| Q3 24 | 0.32× | 0.04× | ||
| Q2 24 | 0.31× | 0.04× | ||
| Q1 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $7.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 22.0% | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.41× | — |
| 过去12个月自由现金流最近4个季度 | $18.7M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流OPRXRXRX
| Q4 25 | $7.1M | $-46.1M | ||
| Q3 25 | $3.2M | $-117.4M | ||
| Q2 25 | $4.6M | $-76.4M | ||
| Q1 25 | $3.9M | $-132.0M | ||
| Q4 24 | $198.0K | $-115.4M | ||
| Q3 24 | $1.8M | $-59.2M | ||
| Q2 24 | $782.0K | $-82.2M | ||
| Q1 24 | $2.1M | $-102.3M |
自由现金流OPRXRXRX
| Q4 25 | $7.1M | $-47.3M | ||
| Q3 25 | $3.2M | $-117.6M | ||
| Q2 25 | $4.6M | $-79.6M | ||
| Q1 25 | $3.8M | $-133.8M | ||
| Q4 24 | $181.0K | $-116.7M | ||
| Q3 24 | $1.8M | $-63.8M | ||
| Q2 24 | $737.0K | $-83.4M | ||
| Q1 24 | $2.1M | $-109.0M |
自由现金流率OPRXRXRX
| Q4 25 | 22.0% | -133.1% | ||
| Q3 25 | 12.2% | -2272.5% | ||
| Q2 25 | 15.6% | -413.9% | ||
| Q1 25 | 17.5% | -907.4% | ||
| Q4 24 | 0.6% | -2567.7% | ||
| Q3 24 | 8.3% | -244.6% | ||
| Q2 24 | 3.9% | -578.5% | ||
| Q1 24 | 10.6% | -789.9% |
资本支出强度OPRXRXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 0.0% | 16.4% | ||
| Q1 25 | 0.1% | 12.4% | ||
| Q4 24 | 0.1% | 28.6% | ||
| Q3 24 | 0.1% | 17.5% | ||
| Q2 24 | 0.2% | 8.2% | ||
| Q1 24 | 0.2% | 48.2% |
现金转化率OPRXRXRX
| Q4 25 | 1.41× | — | ||
| Q3 25 | 4.11× | — | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
